1. Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor. (October 2020) Authors: Janku, F.; Sherman, E.J.; Parikh, A.R.; Feun, L.G.; Tsai, F.; Allen, E.; Zhang, C.; Severson, P.; Inokuchi, K.; Walling, J.; Averbuch, S.; Tarcic, G.; Bollag, G. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗